ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016
Integrin β6 acts as an unfavorable prognostic indicator and promotes cellular malignant behaviors via ERK-ETS1 pathway in pancreatic ductal adenocarcinoma (PDAC).
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- A ternary association of KRas, EphA2, and integrins controls PDAC cell behavior.The Journal of biological chemistry · 2026Article
- Synthesis and preclinical development of a novelEJNMMI radiopharmacy and chemistry · 2026Article
- Article
- Synthesis and Evaluation of a Monomethyl Auristatin E─Integrin αJournal of medicinal chemistry · 2023Article
- Targeting integrin αvβ6 with gallium-68 tris (hydroxypyridinone) based PET probes.Dalton transactions (Cambridge, England : 2003) · 2022Article
- A Comparison of Evans Blue and 4-(Pharmaceutics · 2022Article
- Targeting Integrins for Cancer Therapy - Disappointments and Opportunities.Frontiers in cell and developmental biology · 2022Review
- Review
- Extracellular matrix and its therapeutic potential for cancer treatment.Signal transduction and targeted therapy · 2021Review
- Targeting of promising transmembrane proteins for diagnosis and treatment of pancreatic ductal adenocarcinoma.Theranostics · 2021Review
- SPECT/CT Imaging, Biodistribution and Radiation Dosimetry of aFrontiers in oncology · 2021Article
- Identification of integrin β6 gene promoter and analysis of its transcription regulation in colon cancer cells.World journal of gastrointestinal oncology · 2020Article
- MicroRNA-769-5p Inhibits Pancreatic Ductal Adenocarcinoma Progression by Directly Targeting and Downregulating ETS Proto-Oncogene 1.OncoTargets and therapy · 2019Article
- Therapeutic Radiopharmaceuticals Targeting Integrin αvβ6.ACS omega · 2018Article
- Although it's painful: The importance of stringent antibody validation.PLoS pathogens · 2018Article
- The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review).International journal of molecular medicine · 2017Review
- Integrated expression analysis identifies transcription networks in mouse and human gastric neoplasia.Genes, chromosomes & cancer · 2017Article
- Review and Application of Integrin Alpha v Beta 6 in the Diagnosis and Treatment of Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most deadly cancers and is expected to become the second leading cause of cancer death by 2030. Despite extensive efforts to improve surgical treatment, limited progress has been made. Increasing evidence indicates that integrin β6 plays a crucial role in carcinoma invasion and metastasis. However, the expression and role of β6 in PDAC remain largely unknown. In the present study, we investigated the expression of β6 in PDAC and its potential value as a prognostic factor and therapeutic target. β6 upregulation was identified as an independent unfavorable prognostic indicator. Integrin β6 markedly promoted the proliferation and invasion of pancreatic carcinoma cells and induced ETS1 phosphorylation in an ERK-dependent manner, leading to the upregulation of matrix metalloprotease-9, which is essential for β6-mediated invasiveness of pancreatic carcinoma cells. Accordingly, small interfering RNA-mediated silencing of integrin β6 markedly suppressed xenograft tumor growth in vivo. Taken together, our results suggest that integrin β6 plays important roles in the progression of pancreatic carcinoma and contributes to reduced survival times, and may serve as a novel therapeutic target for the treatment of PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.